Sangita Basnet
Family · Frederick, MDNPI 1053193193
Payments from drug & device makers
Across 72 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$448
- AstraZeneca$203
- AbbVie$163
- GSK$156
- Amgen$109
- Exact Sciences$78
- plus $460 from 15 others
What the payments were for
- Food & beverage$1,617100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $448 |
| AstraZeneca | 12 | $203 |
| AbbVie | 8 | $163 |
| GSK | 7 | $156 |
| Amgen | 2 | $109 |
| Exact Sciences | 3 | $78 |
| Astellas Pharma US Inc | 3 | $58 |
| Lilly USA, LLC | 3 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Nevro Corp. | 2 | $40 |
| Harmony Biosciences LLC | 1 | $38 |
| Bayer | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Biotronik NRO, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| Pfizer | 1 | $18 |
| Merck | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Averitas Pharma Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$115
How this compares
$1,617 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $83,896 |
| MounjaroTirzepatide | 33 | $54,804 |
| EliquisApixaban | 42 | $46,406 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $22,680 |
| FarxigaDapagliflozin Propanediol | 14 | $17,780 |
| JardianceEmpagliflozin | 12 | $13,964 |
| LinzessLinaclotide | 14 | $12,258 |
| SynthroidLevothyroxine Sodium | 24 | $2,503 |
| Rosuvastatin Calcium | 90 | $2,105 |
| Ezetimibe | 11 | $1,910 |
| Memantine Hcl | 36 | $1,397 |
| Gabapentin | 88 | $1,317 |
| Atorvastatin Calcium | 85 | $1,233 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,102 |
| Fluoxetine Hcl | 27 | $941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $448 | $83,89638 claims |
| Lilly USA, LLCMounjaro | $56 | $54,80433 claims |
| PfizerEliquis | $18 | $46,40642 claims |
| GSKTrelegy Ellipta | $156 | $22,68015 claims |
| AstraZenecaFarxiga | $203 | $17,78014 claims |
| AbbVieLinzess, Synthroid | $163 | $14,76138 claims |
| Boehringer IngelheimJardiance | $20 | $13,96412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.
Other family in Frederick
- Teri OneilFrederick$17K
- Sandra RizzoFrederick$10K
- Lindsay BittoFrederick$10K
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.